We feel like a Sitting Duck on the markets.
“It’s waiting that helps you as an investor, and a lot of people just can’t stand to wait.” – Charlie Munger
Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer.
Fair value: $ 32.00
Discount: 48%
Average yearly return: 100%
TOP performer
On May 2, 2017 Exelixis reported first-quarter earnings, posting something many biotechs never achieve: profitability on an operating basis.
No comments:
Post a Comment